Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Tools & Techniques Drug discovery, Informatics

Medicina Ex Machina

Traditionally, pharma companies have been skeptical about the promise of artificial intelligence (AI). But with its potential to bring powerful new tools to the often slow and expensive drug discovery process – and its ability to predict which drugs are most likely to successfully run the clinical trial gauntlet, pharma companies are waking up to the fact that it really could be the future.

In 2017, a collaboration began between Insilico Medicine, an AI company specializing in deep learning for drug discovery, and Juvenescence – a company focused on investing in treatments for age-related diseases and longevity. The aim of the partnership? To find out if AI techniques could enhance drug discovery in the tricky area of age-related diseases, including dementia, diabetes, and cancer, as well as the aging process itself.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!


Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.


Send me the latest from The Translational Scientist.

Sign up now

Related Articles

Research Field Cancer

Cancer and the Microbiome

| Ivan Gladwyn-Ng, Alexander Maue

Research Field Neurological

Redirecting Cell Fate

| Jonathan James

Disease Area Cancer

Two-pronged Attack on Neuroblastoma

| Jonathan James

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts